Table 3.
Mitochondrial transplantation effect to prevent drug-related toxicity.
| Author/Year | Model/Disease | Mitochondria source | Transfer parameters | Clinical & biological evidences | Mitochondrial mechanisms modulation |
|---|---|---|---|---|---|
|
| |||||
| Jin 2024 [90] | C57BL/6N mice Doxorubicin cardiotoxicity |
MSC cells Not specified |
Dose: 3 mg/kg Administration: IV Site: not specified |
Restore ejection fraction and fractional shortening ↓ fibrosis ↓ apoptosis |
↑ ATP level ↑ mito quantity (image) ↑ anti-ox (mRNA Sdhaf2/4) ↓ autophagy (mRNA LC3BII, p62) ↓ autophagosomes (inhibit AMPK/mTOR pathway) |
| Kim 2024 [91] | Sprague Dawley rat Dexamethasone related amyotrophy |
UC-MSC cells Human Xenogeneic |
Doses: 0.5–5 μg/limb Administration: IM Site: soleus |
Positive effect with 5 μg Recover muscle mass, fiber area, desmin, myogenin ↓ lactate |
Act AMPK/AKT/Foxo pathway (↑Akt, ↓ FOXO3, ↓ MuRF-1, ↓ MAFbx) ↑ OXPHOS (CI, II, IV, V activity) ↑ mito biosynthesis (PGC-1, TFAM) |
| Kubat 2024 [92] | Sprague Dawley rat Doxorubicin muscular toxicity |
Femoris Rat Allogenic |
Dose: 6.5 μg mito proteins Administration: IM Sites: 3 tibialis |
No protective effect No effect on apoptosis No effect on inflammation |
↑ anti-ox (succinate DH, SOD) |
| Maia 2023 [93] | SWISS mice Oxaliplatin neurotoxicity |
Liver Mice Allogenic |
Dose: 0.5 mg/kg Administration: IV Site: retro-orbital |
↓ cold mechanical and sensitive alteration ↓ neuro-inflammation (TNFα, TLR4) |
Not investigated |
| Maleki 2023 [94] | Wistar rat Doxorubicin cardiotoxicity |
Liver Rat Allogenic |
Dose: 8*109 mito Administration: IV Site: tail |
Restore ejection fraction and fractional shortening ↓ apoptosis ↓ inflammation (TNFα, IL1β, IL6) |
↑ ATP level ↓ oxidative stress markers (MDA) ↑ anti-ox (SOD, CAT, GPX, GSH) |
| Sun 2023 [95] | C57BL/6 mice Doxorubicin cardiotoxicity |
Heart Mice Allogenic |
Dose: 105 mito Administration: intraventricular Site: cardiac |
↑ ejection fraction and fractional shortening ↓ apoptosis |
↓ Superoxide (mitosox probe) ↑ anti-ox (SOD2, OGG1) ↑ mito function (IDH2, citrate synthase) ↑ mitogenesis (PGC1-b) ↑ fusion (Opa1) ↑ OCR/ECAR ratio Act glutamine & glutamate metabolic pathway |
| Zhang 2023 [96] | C57BL/6 mice Doxorubicin cardiotoxicity |
Heart Mice Allogenic |
Dose: 5*104 mito Administration: intraventricular Site: cardiac |
↑ ejection fraction and fractional shortening | ↑ mito quantity (hs & ms mtDNA) ↓ intracellular ROS, ↑ mito ROS ↑ MMP ↑ baseline and max OCR |
| Alexander 2021 [97] | C57BL/6J mice Cisplatin neurotoxicity |
MSC cells Human Xenogeneic |
Dose: 170 μg mito proteins Administration: intra-nasal | ↑ executive functioning Restore spatial/working memory Restore synaptic damage |
↓ atypical mito morphology ↓ synaptosomal mito damage ↑ anti-ox (Nrf2) |
| Kubat 2021 [98] | Sprague Dawley rat Doxorubicin nephrotoxicity |
MSC cells Rat Allogenic |
Dose: 4*106 mito Administration: injection Site: below kidney capsule | ↑ cellular regeneration ↓ apoptosis ↓ proteinuria |
↑ anti-ox (SOD, GPX) |
| Ulger 2021 [99] | Sprague Dawley rat Acetaminophen hepatotoxicity |
MSC cells Rat Allogenic |
Dose: 8.2*106 mito Administration: injection Site: subscapular spleen |
↓ histological alteration ↓ apoptosis and ALAT |
↓ anti-ox (GSH) |
| Shi 2018 [100] | Sprague Dawley rat Acetaminophen hepatotoxicity |
HepG2 cells Human Xenogeneic |
Dose: 10 mg/kg (fresh or fractioned) Administration: IV Site: tail |
Results obtained only for fresh mito ↓ histological alteration ↓ ALAT and ASAT |
↑ ATP level, only for intact mito ↑ anti-ox (GSH), only for intact mito ↓ ROS, only for intact mito |
Akt: protein kinase B, ALAT: alanine aminotransferase, AMPK: AMP-activated protein kinase, anti-ox: anti-oxidant; ASAT: aspartate aminotransferase, ATP: adenosine tri-phosphate, CAT: catalase, ECAR: extracellular acidification rate, FOXO: forkhead box O, GPX: glutathione peroxidase, GSH: Reduced glutathione, IDH2: isocitrate dehydrogenase 2, IL: interleukin, IM: intra-muscular, IV: intra-veinous, LC3: microtubule-associated protein light chain 3, mito: mitochondria, MAFbx: muscle atrophy F-box, MDA: malondialdehyde, MMP: Mitochondrial membrane potential, MSC: mesenchymal stromal cell, mTOR: mammalian target of rapamycin, MuRF-1: muscle RING finger protein 1, NRF2: nuclear factor erythroid 2, OCR: oxygen consumption rate, OGG1: 8-oxoguanine DNA glycosylase 1, OPA1: optic atrophy 1, OXPHOS: oxidative phosphorylation, PGC1b: Pparg coactivator 1-b, ROS: relative oxygen species, Sdhaf: Succinate dehydrogenase assembly factor 1, SOD: superoxide dismutase, TFAM: mitochondrial transcription factor A, TLR4: Toll-like receptor 4, TNFα: tumor necrosis factor α, UC-MSC: Umbilical-cord MSC, ↑: increase/improve, ↓: decrease.